10. Sale of Research and Development Assets (Tables)

12 Months Ended

Apr. 30, 2019

Discontinued Operations and Disposal Groups [Abstract]

Discontinued operations summary

The following table summarizes the results of discontinued operations for the fiscal years ended April 30, 2019, 2018 and 2017:

	2019		2018			2017
License revenue	$	–	$	25		$	–
Operating expenses:
Research and development		–		6,782			27,992
Selling, general and administrative		–		2,163			1,560
Restructuring charges		–		330			–
Total operating expenses		–		9,275			29,552
Other income		125		–			–
Gain on sale of research and development assets before income taxes		1,000		8,000			–
Income tax expense		284		–			–
Income (loss) from discontinued operations, net of tax	$	841	$	(1,250	)	$	(29,552	)

The following table includes only the assets and liabilities of discontinued operations as of April 30, 2018. There were no assets or liabilities related to discontinued operations as of April 30, 2019:

	2018
Assets:
Other receivables	$	5,000
Total assets of discontinued operations	$	5,000
Liabilities:
Accounts payable	$	32
Accrued clinical trial and related fees		3,613
Accrued payroll and related costs		614
Other liabilities		291
Total liabilities of discontinued operations	$	4,550